The vaccine against Covid-19 produced by AstraZeneca is effective after the first dose. Particularly, the level of the protection makes 70% as the company reported.
“The primary analysis of the Phase III clinical trials from the UK, Brazil and South Africa, published as a preprint in The Lancet confirmed COVID-19 Vaccine AstraZeneca is safe and effective at preventing COVID-19,” the message said.
It is reported that the Phase III clinical trials show 100% protection from the severe consequences, hospitalization and death from the coronavirus.
Thus, the studies in the UK, Brazil and South Africa showed the efficacy of the vaccine at the level of 76% after the first dose with protection maintained to the second dose. With an interval of 12 weeks between them and more, the efficacy of the vaccine increases up to 82%.
Moreover, the studies confirmed that AstraZeneca vaccine reduces asymptomatic transmission of the virus by 67% after the first dose and by 50% after the second. The analysis of the information is based on the rates of over 17,000 volunteers who had 332 symptomatic cases.
The vaccine might be stored and transported in normal refrigerated conditions (two-eight degrees Celsius) for at least six months and administered within existing healthcare settings.
Earlier, the European Commission gave approval for the use of the Covid-19 vaccine developed by AstraZeneca, the final step to allowing Europe to use it across the Union.
AstraZeneca is to cut deliveries of its Covid-19 vaccine to the EU by 60% in the first quarter of the year due to production problems.
As we reported, due to vaccine supply delays, the European Union has stepped up pressure on the British-Swedish pharmaceutical company AstraZeneca. EU states are considering suing AstraZeneca for breach of contract.
Watch related video: